Hay Group: Big Pharma CEO Compensation Plans Fails to Spur Innovation

More News:

• 06/18/2013 Aragon Purchased For $650M+From USA Today

  Johnson & Johnson has agreed to buy Aragon Pharmaceuticals for at least $650 million in cash.

• 06/18/2013 ASME BPE Certifies MaxPure Stainless-Steel Fittings

  TEK Stainless Piping Products announces certification of MaxPure, EGMO’S stainless-steel fitting product line for bioprocessing industry

• 06/18/2013 Supreme Court Rules Against 'pay-to-delay'From Economic Times

  Big pharma companies lose in Supreme Court's 'pay-to-delay' decision.

• 06/18/2013 BioScrip Acquires CarePoint for $223 MillionFrom Bloomberg Businessweek

  BioScrip Inc. plans to expand its drug infusion business with a new acquisition of CarePoint for $223 million.

• 06/17/2013 Endress+Hauser Offers Online Thermowell Sizing Calculator

  Free, online thermowell calculation tool compliant with new ASME PTC 19.3 TW-2010 standards simplifies engineer work

• 06/14/2013 Supreme Court DNA Ruling Could Hurt Biotech IndustryFrom The Denver Post Politics

  Critics said the ruling would discourage other companies and financial backers from investing in more genetic sequencing research

• 06/14/2013 Supreme Court Says No to Patenting Human GenesFrom The Scientist

  The Court unanimously ruled that isolated sequences of human DNA are not eligible for patent protection, but artificial sequences can be patented

• 06/13/2013 All-new Pharma EXPO Debuts in November 2014

  Co-located with PACK-EXPO International, ISPE Pharma EXPO will be held in Chicago

• 06/13/2013 Canadian Health Authority Accepts Use of Roche's Rapid Mycoplasma Detection TestFrom Roche

  Roche’s Rapid Mycoplasma Detection Test MycoTOOL Receives Acceptance from Canadian Authorities for Release Testing of Biopharmaceutical Roche Product

• 06/13/2013 Over 200 Cardiovascular Disease Drugs in DevelopmentFrom Drug Store News

  According a recent report, 215 drugs are now under development for heart disease and stroke.

• All news »